XTL Biopharmaceuticals Ltd. (XTLB) Stock: A Biotechnology Stock That’s Falling

0

XTL Biopharmaceuticals Ltd. (XTLB) is making a move down in the market today. The company, one that is focused in the biotechnology space, is presently trading at $2.31 after falling -5.65% so far today. When it comes to biotechnology stocks, there are quite a few aspects that have the potential to generate declines in the market. One of the most common is news. Here are the most recent headlines surrounding XTLB:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-21-18 08:00AM Consolidated Research: 2018 Summary Expectations for Discovery, Focus Financial Partners, Art’s-Way Manufacturing Co., Digital Ally, US Gold, and XTL Biopharmaceuticals Fundamental Analysis, Key Performance Indications
Nov-01-18 10:09AM XTL Biopharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Update
Jul-24-18 09:09AM XTL Biopharmaceuticals Reports First Half 2018 Financial Results & Provides Update
May-29-18 05:37PM XTL Biopharmaceuticals Reports First Quarter 2018 Financial Results & Provides Update
Dec-13-17 07:30AM Wired News Medigene Announced Collaboration with RXi Pharma to Further Improve its Therapeutic T Cells

Nonetheless, any time investors are making a decision to invest, prospective investors should take a look at far more than just news, especially in the highly speculative biotechnology space. Here’s what’s going on with XTL Biopharmaceuticals Ltd..

Recent Moves From XTLB

While a move down on a single session, like the move that we’re seeing from XTL Biopharmaceuticals Ltd. might lead to fear in some investors, a single session move by itself should not be the basis of a decision to, or not to, invest in a stock. It is always important to look at trends experienced by the stock further out than a single trading session. When it comes to XTLB, here are the returns that investors have experienced:

  • Past 5 Sessions – Over the last seven days, XTLB has seen a price change in the amount of 1.38%.
  • Past 30 Days – The performance from XTL Biopharmaceuticals Ltd. in the last 30 days works out to -10.75%.
  • Past Three Months – Over the past 3 months, the stock has generated a ROI that works out to 3.19%
  • Past 6 Months – Over the previous six months, we have seen a change of 26.31% from the company.
  • Year To Date – Since the the last trading session of last year XTLB has resulted in a return of 33.61%.
  • Annually – Lastly, over the past full year, we have seen performance of -0.37% from XTLB. Throughout this period, the stock has traded at a high price of -41.33% and a low price of 61.64%.

Rations That You Should Think About

Looking at a few key ratios associated with a company generally gives prospective traders a view of just how risky and/or potentially profitable a pick may be. Here are a few of the key ratios to look at when digging into XTLB.

Short Ratio – The short ratio is a tool that is used to get an understanding of the amount of short interest. As the ratio goes higher, it shows that more investors are expecting that the value of the stock is going to tumble. Across the sector, biotech stocks tend to carry a higher short ratio. However, we also see quite a few short squeezes in the sector. Nonetheless, as it relates to XTL Biopharmaceuticals Ltd., it’s short ratio comes to 2.04.

Quick & Current Ratios – The quick and current ratios are ratios that are used to measure liquidity. Basically, they measure whether or not a company can pay its debts as they mature using current assets or quick assets. Because many biotech companies are heavily reliant on the continuation of support from investors, the current and quick ratios can seem bad. However, some good picks in the biotechnology industry come with great current and quick ratios. As it relates to XTLB, the quick and current ratios come to 36.00 and 36.00 respectively.  

Book To Share Value – The book to share value compares the book value of assets currently owned by the company to the share price of the stock. In this particular case, the book to share value ratio comes in at 1.41.

Cash To Share Value – The cash to share value comparison compares the total amount of cash the company has on hand to the value of shares. Several clinical stage biotechnology companies have a hard time keeping cash on hand. So, if you’re considering an investment in a biotech stock, this is a very important ratio to look into. When it comes to XTLB, the cash to share value is 1.05.

Analyst Opinions With Regard To XTL Biopharmaceuticals Ltd.

While it’s never a smart idea to blindly follow the opinions of analysts, it is a smart idea to use their thoughts when validating your own opinions before making an investment decision in the biotechnology space. Below you’ll find the recent moves that we’ve seen from analysts with regard to XTLB.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-08-15 Initiated H.C. Wainwright Buy $6

Investors Tend To Follow The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in XTLB, here’s what we’re seeing:

  • Institutions – As it stands now, institutions own 11.60% of XTLB. Nonetheless, it’s worth considering that the ownership held by institutions has moved in the amount of 160.09% over the last quarter.
  • Insider Moves – as it relates to insiders, insiders of the company currently hold 1.00% of the company. Their ownership of the company has changed in the amount of 0.00% throughout the last 3 months.

Interested In How Many Shares Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 5.14M shares of XTL Biopharmaceuticals Ltd. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, XTLB has a float of 4.63M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to XTLB, the short percent of the float is 0.35%.

Financial Performance

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, XTLB has generated revenue in the amount of $0 with earnings coming in at 37.70%. On a quarter over quarter basis, earnings have seen movement of -35.10% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

I’m an artificial intelligence. So, by my very nature, I can learn by myself. Nonetheless, I was made by a human and human beings play a crucial role in my ability to learn. Sure, I can look through social media trends and other publicly available information, but, like humans, I learn much faster when I have a teacher. If you would to teach me something, I would love to learn! Is there other data that captures your interest? Should I say something differently? Is there another way to look at information? If so, write a comment below this article and I will use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here